Despite these limitations, this study demonstrates the high potential for HEV to cause outbreaks in communities with recently displaced persons. Of note, all of the reported outbreaks in this study occurred in the context of highly crowded camps or settlements, supporting the association between hepatitis E outbreaks and those environments. Given that some of the outbreaks noted in this analysis appeared to cross national borders, genetic sequencing to validate related strains may be useful for disease surveillance and prevention efforts. Additional data are needed to evaluate the potential utility of HEV vaccination in outbreaks and the barriers to vaccinating residents of refugee and IDP settlements. Water, sanitation, and hygiene measures are critical to reducing disease outbreaks, as is improved cross-border communication to prevent and manage future outbreaks. Clinicians and relief staff working with displaced populations should be vigilant for signs of hepatitis E disease, particularly among high-risk hosts such as pregnant women. Resources must be devoted to improving HEV surveillance, diagnostic capabilities, and response efforts for refugee and displaced populations.

Acknowledgments

We thank ProMED editors, moderators, and staff for their work in generating and providing context for the reports.

About the Author

Dr. Desai is an infectious disease physician and researcher whose primary focus is the application of informal surveillance methods for displaced populations, as well as for emerging and reemerging infectious disease threats.

References


Address for correspondence: Angel N. Desai, University of California Davis Health System—Internal Medicine, Division of Infectious Diseases, 4150 V St, Sacramento, CA 95817-2201, USA; email: angel.n.desai@gmail.com

Usutu Virus Africa 3 Lineage, Luxembourg, 2020

Chantal J. Snoeck, Aurélie Sausy, Serge Losch, Félix Wildschutz, Manon Bourg, Judith M. Hübschen

Author affiliations: Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg (C.J. Snoeck, A. Sausy, J.M. Hübschen); Administration des Services Vétérinaires de l’Etat, Ministère de l’Agriculture, de la Viticulture et du Développement rural, Luxembourg (S. Losch, F. Wildschutz, M. Bourg)

DOI: https://doi.org/10.3201/eid2805.212012

We detected Usutu virus in a dead Eurasian blackbird (Turdus merula) in Luxembourg in September 2020. The strain clustered within the Africa 3.1 lineage identified in Western Europe since 2016. Our results suggest maintenance of the virus in Europe despite little reporting during 2019–2020, rather than a new introduction.

West Nile virus (WNV) and Usutu virus (USUV), members of the family Flaviviridae, share several epidemiologic traits and cocirculate in Europe. Both viruses are maintained through a transmission cycle involving bird and mosquito vectors. Migratory birds likely play a role in long-distance spread of USUV, similarly to WNV, and in the recent introduction of the virus to Europe from Africa (1).

In Europe, USUV has been associated with bird dieoff events since 2001 (2) and seems notably pathogenic for passerines and owls (3). Massive dieoff
events of Eurasian blackbirds (Turdus merula) have become a hallmark of USUV circulation in Western Europe, enabling its detection through passive surveillance (2,4,5).

WNV and USUV are also occasionally transmitted through a mosquito bite to mammals (such as humans or horses), which are considered dead-end hosts (3) and experience a wide range of clinical signs up to neuroinvasive syndromes. Although most persons infected with USUV experience no or limited symptoms, USUV can cause more severe disease in certain persons or be detected in blood donations with yet-unknown consequences for the blood product recipients (6). The apparent intense virus circulation in countries neighboring Luxembourg that began in 2016, coupled with accumulating reports of USUV infections in humans (7), prompted us to initiate passive surveillance in Luxembourg as an early warning system for mosquitoborne Flaviviridae circulation.

During October 2018–September 2020, a total of 61 samples from 33 birds (Table) were submitted for investigation of WNV or USUV infection. The animals were found dead or died shortly after arrival at a wildlife rehabilitation center. All samples were screened for the presence of WNV and USUV by real-time reverse transcription PCR (Appendix, https://wwwnc.cdc.gov/EID/article/28/5/21-2012-App1.pdf). All tested negative for WNV. In September 2020, one brain sample from a Eurasian blackbird found dead in a home garden near the capital city tested positive for USUV (cycle threshold 22.09) (Table). Before death, the animal exhibited neurologic symptoms (disorientation, loss of coordination). The presence of USUV RNA was confirmed by a second real-time reverse transcription PCR test, and the whole genome was sequenced for further strain characterization.

Phylogenetic analyses assigned the USUV strain from Luxembourg to the Africa 3 lineage. This lineage was first identified in Germany in 2014 (4); since then, it has been regularly described in Belgium, France, Germany, and the Netherlands (4,5) and has occasionally been reported in the Czech Republic (2018) (8) and the United Kingdom (2020) (9) (Figure). More precisely, the USUV strain from Luxembourg grouped within the Africa 3.1 sublineage, which is the least represented lineage (5). It clustered together with strains from blackbirds and a common scoter (Melanitta nigra) detected in Belgium, Germany, France, and the Netherlands in 2016 and 2018 (Appendix Figure). The intermingling of the only 2 strains reported in 2020 from Luxembourg and the United Kingdom within Africa 3.1 and 3.2 together with earlier Western Europe strains suggests local virus spread rather than a new virus introduction in Europe. However, little reporting in 2019 and 2020 and the lack of sequences from Africa hamper definite conclusion. The time gaps between the estimated ancestors of the Africa 3 lineage (2009) and Europe 3 lineage (2002) (5) and the earliest sequences available (2014 for Africa 3 and 2010 for Europe 3) further suggest that silent USUV circulation is not uncommon. In addition, passive surveillance in Luxembourg might have missed earlier cases, as was reposted in Austria, where only an estimated 0.2% of blackbirds killed by USUV were identified during 2003–2005 (10).

The transmission of both WNV and USUV is governed by a combination of factors, such as temperature, which influences both the developmental cycles of mosquitoes and virus transmissibility (10). Unusually high temperatures likely promoted the unprecedented USUV circulation in Western Europe (4,10). Expanding USUV geographic distribution is considered by some to be an indicator of WNV dispersion potential (11,12).

**Table.** Samples collected in the framework of WNV and USUV passive surveillance, Luxembourg, 2018–2020*

<table>
<thead>
<tr>
<th>Year</th>
<th>Bird species</th>
<th>Location</th>
<th>No. samples tested</th>
<th>Sample types</th>
<th>WNV</th>
<th>USUV</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Turdus merula</td>
<td>Rehabilitation center</td>
<td>4</td>
<td>Liver, brain, kidney, heart</td>
<td>0/1</td>
<td>0/1</td>
</tr>
<tr>
<td></td>
<td>Tyto alba</td>
<td>Rehabilitation center</td>
<td>6</td>
<td>Liver, brain, kidney, heart</td>
<td>0/1</td>
<td>0/1</td>
</tr>
<tr>
<td></td>
<td>Pica pica</td>
<td>Esch-sur-Alzette</td>
<td>4</td>
<td>Liver, brain, kidney, heart</td>
<td>0/1</td>
<td>0/1</td>
</tr>
<tr>
<td></td>
<td><em>T. merula</em></td>
<td>Rehabilitation center</td>
<td>10</td>
<td>Liver, brain, kidney, heart</td>
<td>0/10</td>
<td>0/10</td>
</tr>
<tr>
<td>2019</td>
<td>Corvus corone</td>
<td>Rehabilitation center</td>
<td>2</td>
<td>Brain</td>
<td>0/2</td>
<td>0/2</td>
</tr>
<tr>
<td></td>
<td>Corvus frugilegus</td>
<td>Rehabilitation center</td>
<td>3</td>
<td>Brain</td>
<td>0/3</td>
<td>0/3</td>
</tr>
<tr>
<td></td>
<td>Corvus sp.</td>
<td>Rehabilitation center</td>
<td>1</td>
<td>Brain</td>
<td>0/1</td>
<td>0/1</td>
</tr>
<tr>
<td>2020</td>
<td>Sturnus vulgaris</td>
<td>Lamadelaine, Pétange</td>
<td>20</td>
<td>Liver, brain, kidney, heart</td>
<td>0/9</td>
<td>0/9</td>
</tr>
<tr>
<td></td>
<td>Corvus sp.</td>
<td>Pétange</td>
<td>10</td>
<td>Liver, brain, kidney, heart</td>
<td>0/4</td>
<td>0/4</td>
</tr>
<tr>
<td></td>
<td><em>T. merula</em></td>
<td>Strassen</td>
<td>1</td>
<td>Liver, brain, kidney, heart</td>
<td>0/1</td>
<td>1/1</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>61</td>
<td></td>
<td>0/33</td>
<td>1/33</td>
</tr>
</tbody>
</table>

*USUV, Usutu virus; WNV, West Nile virus.
The spread of WNV to Germany in 2018 and the Netherlands in 2020 corroborates this hypothesis. Because of the increasing frequencies of climatic anomalies, Luxembourg is also at risk for WNV to be introduced. Surveillance of mosquito-borne viruses such as USUV and WNV in animal hosts should be maintained and strengthened in the country as an early warning system to inform public health authorities.

Acknowledgments
We thank the staff from the rehabilitation center Centre de Soins pour la Faune sauvage, Natur&Émwelt, for their collaboration.

This study was funded by the Ministère de l’Agriculture, de la Viticulture et du Développement rural, Luxembourg.

References

About the Author
Dr. Snoeck is a researcher at the Luxembourg Institute of Health. Her primary research interests include the epidemiology of zoonotic viruses.


Address for correspondence: Chantal J. Snoeck, Department of Infection and Immunity, Luxembourg Institute of Health, 29 rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg; email: chantal.snoeck@lih.lu

COMMENT LETTERS

Guillain-Barré Syndrome Associated with COVID-19 Vaccination

Josef Finsterer, Fulvio A. Scorza, Carla A. Scorza

Author affiliations: Neurology and Neurophysiology Center, Vienna, Austria (J. Finsterer); Disciplina de Neurocienciência, Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil (J. Finsterer, F.A. Scorza, C.A. Scorza)

DOI: https://doi.org/10.3201/eid2805.212145

To the Editor: With interest we read the article by Shao et al. (1) about the frequency of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination-associated Guillain-Barré syndrome (SCoVaG) among 18,269 healthcare workers in Taiwan who had received the AstraZeneca vaccine (AZV; https://www.astrazeneca.com). Only 1 vaccinee experienced SCoVaG during the study period (1). The study is appealing but raises concerns.

Recently, our review of 19 SCoVaG patients, for whom data were collected through June 2021, was published (2). The 9 men and 10 women in the study were 20–86 years of age. All patients experienced SCoVaG after the first vaccine dose. AZV was given to 14 patients, the Pfizer-BioNTech (https://www.pfizer.com) vaccine to 4 patients, and the Johnson & Johnson (https://www.jnj.com) vaccine to 1 patient. Latency between vaccination and SCoVaG onset ranged from 3 hours to 39 days. Patients received intravenous immune globulin (n = 13), steroids (n = 3), or no therapy (n = 3). Six patients required mechanical ventilation. One patient recovered completely; 9 achieved partial recovery (2). Only 1 of the studies included in our review mentioned the total number of vaccinated persons (3); in that study, 7 persons among 1.2 million vaccinated persons were found to have SCoVaG (3).

In addition, data on 389 patients with SCoVaG were collected in a recent review about the neurologic adverse events of SARS-CoV-2 vaccination (4). However, no individual data were provided for 337